BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16359782)

  • 1. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Maltais R; Fournier MA; Poirier D
    Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
    Laplante Y; Poirier D
    Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
    Tchédam-Ngatcha B; Luu-The V; Poirier D
    J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
    Laplante Y; Rancourt C; Poirier D
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
    Aka JA; Mazumdar M; Lin SX
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
    Bydal P; Auger S; Poirier D
    Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
    Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
    Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
    Ngatcha BT; Luu-The V; Poirier D
    Bioorg Med Chem Lett; 2000 Nov; 10(22):2533-6. PubMed ID: 11086723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
    Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
    Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
    Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
    Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.